Dual integrin αvβ 3 and NRP-1-Targeting Paramagnetic Liposome for Tumor Early Detection in Magnetic Resonance Imaging

[1]  A. Dublin,et al.  Magnetic Resonance Imaging (MRI) Gadolinium , 2019 .

[2]  Weibo Cai,et al.  Dual-Targeted Molecular Imaging of Cancer , 2018, The Journal of Nuclear Medicine.

[3]  Jeffrey J. Neil.  Magnetic Resonance Imaging (MRI) , 2003 .

[4]  G. Rubini,et al.  Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives , 2017, International journal of molecular sciences.

[5]  Xiaoyuan Chen,et al.  Clinical Translation of a Dual Integrin αvβ3– and Gastrin-Releasing Peptide Receptor–Targeting PET Radiotracer, 68Ga-BBN-RGD , 2017, The Journal of Nuclear Medicine.

[6]  P. Zielenkiewicz,et al.  Plant MicroRNAs—Novel Players in Natural Medicine? , 2016, International journal of molecular sciences.

[7]  K. Abnous,et al.  Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. , 2016, Colloids and surfaces. B, Biointerfaces.

[8]  K. Plate,et al.  Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. , 2016, Neuro-oncology.

[9]  Fangfang Wang,et al.  cRGD-conjugated magnetic-fluorescent liposomes for targeted dual-modality imaging of bone metastasis from prostate cancer , 2015, Journal of liposome research.

[10]  Min-hao Lv,et al.  A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy , 2014, Oncology letters.

[11]  D. Pan,et al.  Imaging Integrin αvβ3 and NRP-1 Positive Gliomas with a Novel Fluorine-18 Labeled RGD-ATWLPPR Heterodimeric Peptide Probe , 2014, Molecular Imaging and Biology.

[12]  Clemens Decristoforo,et al.  Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles , 2013, International journal of nanomedicine.

[13]  Takeshi Yoshikawa,et al.  Magnetic Resonance Imaging for Lung Cancer , 2013, Journal of thoracic imaging.

[14]  Klaas Nicolay,et al.  Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[15]  W. Zhou,et al.  RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studies. , 2011, European journal of radiology.

[16]  Xiaoyuan Chen,et al.  Peptide heterodimers for molecular imaging , 2011, Amino Acids.

[17]  Thomas E Yankeelov,et al.  Magnetic resonance in the era of molecular imaging of cancer. , 2011, Magnetic resonance imaging.

[18]  A. Bogdanov,et al.  Molecular magnetic resonance contrast agents for the detection of cancer: past and present. , 2011, Seminars in oncology.

[19]  W. Zhou,et al.  Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes , 2010, Nanotechnology.

[20]  H. Harashima,et al.  Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. , 2010, International journal of pharmaceutics.

[21]  Klaas Nicolay,et al.  Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. , 2010, Nano letters.

[22]  H. Heerklotz.  Interactions of surfactants with lipid membranes , 2008, Quarterly Reviews of Biophysics.

[23]  Ananth Annapragada,et al.  T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents--effect of liposome size and internal gadolinium concentration. , 2008, Academic radiology.

[24]  Marie-France Bellin,et al.  Extracellular gadolinium-based contrast media: an overview. , 2008, European journal of radiology.

[25]  Eun Kyoung Ryu,et al.  18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging , 2008, Journal of Nuclear Medicine.

[26]  Stavroula Sofou,et al.  Antibody-targeted liposomes in cancer therapy and imaging , 2008, Expert opinion on drug delivery.

[27]  M. Crépin,et al.  Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. , 2006, Life sciences.

[28]  Ruud P. M. Dings,et al.  Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy , 2006, Proceedings of the National Academy of Sciences.

[29]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[30]  F. Guillemin,et al.  A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Klaas Nicolay,et al.  Lipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging , 2006, NMR in biomedicine.

[32]  D. Balvay,et al.  Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment , 2006, Abdominal Imaging.

[33]  G. Bormans,et al.  In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1. , 2004, Nuclear medicine and biology.

[34]  R. Kontermann,et al.  Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. , 2004, Protein engineering, design & selection : PEDS.

[35]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[36]  Jo Klaveness,et al.  Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. , 2002, International journal of pharmaceutics.

[37]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[38]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[39]  D. Cheresh,et al.  Role of alpha v integrins during angiogenesis. , 2000, Cancer journal.

[40]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.

[41]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[42]  E. Unger,et al.  Liposomes as MR contrast agents: Pros and cons , 1991, Magnetic resonance in medicine.

[43]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[44]  Kai Temming.  New ways in RGD-peptide mediated drug targeting to angiogenic endothelium : On the nature of drugs, linkers, and carriers. , 2007 .

[45]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[46]  V. Caride.  Liposomes as carriers of imaging agents. , 1985, Critical reviews in therapeutic drug carrier systems.